Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.

Detalles Bibliográficos
Autores principales: Welen, Karin, Rosendal, Ebba, Freyhult, Eva, Fors Connolly, Anne-Marie, Överby, Anna K., Josefsson, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association of Urology. Published by Elsevier B.V. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837902/
https://www.ncbi.nlm.nih.gov/pubmed/35168845
http://dx.doi.org/10.1016/j.eururo.2022.02.001
_version_ 1784649993405071360
author Welen, Karin
Rosendal, Ebba
Freyhult, Eva
Fors Connolly, Anne-Marie
Överby, Anna K.
Josefsson, Andreas
author_facet Welen, Karin
Rosendal, Ebba
Freyhult, Eva
Fors Connolly, Anne-Marie
Överby, Anna K.
Josefsson, Andreas
author_sort Welen, Karin
collection PubMed
description
format Online
Article
Text
id pubmed-8837902
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Association of Urology. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88379022022-02-14 Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Welen, Karin Rosendal, Ebba Freyhult, Eva Fors Connolly, Anne-Marie Överby, Anna K. Josefsson, Andreas Eur Urol Letter to the Editor European Association of Urology. Published by Elsevier B.V. 2022-05 2022-02-12 /pmc/articles/PMC8837902/ /pubmed/35168845 http://dx.doi.org/10.1016/j.eururo.2022.02.001 Text en © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Welen, Karin
Rosendal, Ebba
Freyhult, Eva
Fors Connolly, Anne-Marie
Överby, Anna K.
Josefsson, Andreas
Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title_full Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title_fullStr Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title_full_unstemmed Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title_short Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
title_sort re: chen dong, sung-lang chen, and wen-wei sung’s letter to the editor re: karin welén, ebba rosendal, magnus gisslén, et al. a phase 2 trial of the effect of antiandrogen therapy on covid-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. eur urol. 2022;81:285–93.
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837902/
https://www.ncbi.nlm.nih.gov/pubmed/35168845
http://dx.doi.org/10.1016/j.eururo.2022.02.001
work_keys_str_mv AT welenkarin rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593
AT rosendalebba rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593
AT freyhulteva rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593
AT forsconnollyannemarie rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593
AT overbyannak rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593
AT josefssonandreas rechendongsunglangchenandwenweisungslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593

Ejemplares similares